Dataset Information


T-cell immunogenicity, gene expression profile and safety of four heterologous prime-boost combinations of HIV vaccine candidates in healthy volunteers – results of the randomized multi-arm phase I/II ANRS VRI01 trial

ABSTRACT: Heterologous prime-boost strategies are of interest for HIV vaccine development. The order of prime-boost components could be important for the induction of T-cell responses. In this phase I/II multi-arm trial, three vaccine candidates were used as prime or boost: MVA HIV-B (coding for Gag, Pol, Nef); HIV LIPO-5 (5 lipopeptides from Gag, Pol, Nef); DNA GTU-MultiHIV B (coding for Rev, Nef, Tat, Gag, Env gp160 clade B). Healthy volunteers (n=92) were randomized to four groups: 1) MVA at weeks (W) 0/8 + LIPO-5 at W20/28 (M/L); 2) LIPO-5 at W0/8 + MVA at W20/28 (L/M); 3) DNA at W0/4/12 + LIPO-5 at W20/28 (G/L); 4) DNA at W0/4/12 + MVA at W20/28 (G/M). Frequency of IFNγ-ELISpot responders at W30 was 33%, 43%, 0% and 74%, respectively. Only MVA-receiving groups were further analyzed. Gene expression profiles of 79 subjects at different timepoints were analyzed by Illumina Whole-Genome Gene Expression BeadChips. Significant whole blood gene expression changes were observed two weeks after the first MVA injection, regardless of its use as prime or boost. An MVA gene signature was identified, including 86 genes mainly related to cell cycle pathways. Three prime-boost strategies led to CD4+ and CD8+ T cell responses and to a whole blood gene expression signature primarily due to their MVA HIV-B component.

ORGANISM(S): Homo sapiens

PROVIDER: GSE196172 | GEO | 2022/04/15


Dataset's files

Action DRS
Items per page:
1 - 1 of 1

Similar Datasets

| S-EPMC8104102 | BioStudies
| E-GEOD-39506 | BioStudies
2013-07-30 | E-GEOD-39506 | ArrayExpress
| S-EPMC3458867 | BioStudies
| S-EPMC6789790 | BioStudies
| S-EPMC3572184 | BioStudies
2013-07-30 | GSE39506 | GEO
| S-EPMC6116222 | BioStudies
| S-EPMC3334902 | BioStudies
| S-EPMC3900398 | BioStudies